A dispute with its manufacturing partner has prompted holographicdisplay developer Voxel of Laguna Hills, CA, to begin lookingfor an alternative source for development and manufacturing ofits Voxcam systems. The dispute began in December, when
A dispute with its manufacturing partner has prompted holographicdisplay developer Voxel of Laguna Hills, CA, to begin lookingfor an alternative source for development and manufacturing ofits Voxcam systems. The dispute began in December, when Voxelannounced that it believed its current vendorlaser systemdeveloper General Scanningwas in breach of contract for allegedlyfailing to meet engineering specifications and delivery datesfor the Voxcam imager, a central element in Voxel's digital holographysystem (SCAN 1/22/97).
The dispute between Voxel and General Scanning, of Watertown,MA, is now headed for binding arbitration. Meanwhile, Voxel hasdecided to accelerate its alternative manufacturing program dueto several factors, such as tests by the company that Voxel believesconfirm the engineering shortcomings at the root of its disputewith General Scanning. Under its contract with General Scanning,Voxel had been prohibited from using another manufacturing partner,but that provision was waived when the dispute went to arbitration.
Voxel's alternative manufacturing program will include securingsubsystems from qualified vendors and will also include performingfinal assembly and testing in-house for a pilot production run.A system integrator for volume manufacturing will also be selected.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.